All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

Customizing first-line BTK inhibitors for CLL

with Gilles Salles, Paolo Ghia, and Francesc Bosch

Wednesday, October 23, 2024
18:30-19:30 BST

Register now

This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.

  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2022-09-28T14:21:24.000Z

Visual abstract | Rehabilitation strategies for patients undergoing CAR T-cell therapy

Sep 28, 2022
Share:
Learning objective: After viewing this visual abstract, learners will be able to recall key rehabilitation needs for patients undergoing CAR T-cell therapy.

The Lymphoma Hub is happy to present a visual abstract summarizing rehabilitation needs associated with CAR T-cell therapies. There is currently a lack of literature focused on the rehabilitation needs of patients undergoing CAR T-cell therapy; however, rehabilitation strategies can be extrapolated from data on patients who have completed treatment for lymphoma and multiple melanoma and those who receive allogeneic HSCT. Patients frequently present functional and neurological deficits associated with their condition, which are often exasperated by CAR T-cell therapy. These patients can benefit from multifaceted rehabilitation strategies before, during, and after treatment, which can improve their quality of life and treatment outcomes.


Visual Abstract

To download this visual abstract, click below.

Download here

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox